In vivo perturbations and single-cell RNA-seq reveal cell-type-specific STAT1-IFNg signaling in regulation of trained immunity in tissue-resident immune cells.
ImmunityBio, Inc. (NASDAQ:IBRX) released progress in its ongoing FDA discussions regarding three areas of its clinical ...
ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced significant progress in its ongoing ...
The investigational anti-PD-1 monoclonal antibody is showing positive topline results from the phase 3 CREST trial.
Imagine unlocking the code to life—a master key capable of extending human existence far beyond its natural limits. While ...
Scientists at the University of Florida are testing a new type of citrus tree that can fight off the tiny insects responsible ...
Scientists at the University of Florida are testing a new type of citrus tree that can fight off the tiny insects responsible ...
Investing.com -- ImmunityBio, an immunotherapy company, saw its shares surge by up to 20%, marking the most significant intraday rise since October 28.
NYSE:PFE) Pfizer's Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer ...
Adding a PD-1 antibody to BCG led to improved event-free survival in patients with non–muscle invasive bladder cancer.
Intravenous BCG vaccine with a built-in kill-switch was found to be at least as effective as regular tuberculosis vaccine in protecting monkeys against infection.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback